`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`————————————————
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`v.
`SANOFI-AVENTIS DEUTSCHLAND GMBH,
`Patent Owner.
`
`————————————————
`Case No. IPR2018-01676
`Patent No. 8,603,044
`————————————————
`
`
`MYLAN PHARMACEUTICALS INC.
`UNOPPOSED MOTION FOR PRO HAC VICE RECOGNITION
`37 CFR §42.10(c)
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2018-01676
`Patent No. 8,603,044
`
`I.
`
` PRECISE RELIEF REQUESTED
`
`Petitioner (Mylan) moves for Elham F. Steiner to be recognized pro hac vice
`
`for this proceeding. 37 CFR §42.10(c); Paper 6, citing Unified Patents, Inc. v.
`
`Parallel Iron, LLC, IPR2013-00639, Paper 7 (2013) (representative). Patent Owner
`
`(Sanofi) has indicated that it will not oppose. A Declaration (EX1040) from Ms.
`
`Steiner accompanies this Motion.
`
`II. STATEMENT OF FACTS
`
`1. Ms. Steiner is a member in good standing of the state bars of New York
`
`and California, of the United States Court of Appeals for the Federal Circuit, and of
`
`numerous United States District Courts. EX1040, ¶1.
`
`2. Ms. Steiner has not been suspended or disbarred from practice before any
`
`court or administrative body. Id., ¶2.
`
`3.
`
`No court or administrative body has denied an application for admission
`
`from Ms. Steiner. Id., ¶3.
`
`4.
`
`No court or administrative body has imposed sanctions or contempt
`
`citations imposed on Ms. Steiner. Id., ¶4.
`
`5. Ms. Steiner has read and will comply with the Office Patent Trial
`
`Practice Guide (and update) and the Board’s Rules of Practice for Trials set forth in
`
`part 42 of title 37 of the Code of Federal Regulations. Id., ¶5.
`
`-2-
`
`
`
`Case No. IPR2018-01676
`Patent No. 8,603,044
`
`
`6. Ms. Steiner agrees to be subject to the USPTO Rules of Professional
`
`Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and to disciplinary jurisdiction under
`
`37 C.F.R. § 11.19(a). Id., ¶6.
`
`7. Within the last three years, Ms. Steiner only appeared pro hac vice before
`
`the Board in Mylan Technologies, Inc. v. MonoSol RX, LLC (IPR2017-00200) and in
`
`related proceedings for Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland
`
`GmbH (IPR2017-01526 and IPR2017-01528). Id., ¶7.
`
`8. Ms. Steiner is counsel for Mylan GmbH in the related district court
`
`litigation with Sanofi-Aventis U.S. LLC, et al. v. Mylan GmbH, et al., No. 2:17-cv-
`
`09105 (D.N.J.), filed October 24, 2017. As a result, Ms. Steiner has particular
`
`experience and familiarity with the substantive and technical issues involved in these
`
`proceedings from that representation, and from coordination in these proceedings. Id.,
`
`¶8.
`
`9. Ms. Steiner is a patent litigation attorney with experience representing
`
`clients in multiple jurisdictions, including United States District Courts and the
`
`Federal Circuit Court of Appeals. Ms. Steiner has experience in all stages of litigation,
`
`from preliminary injunction through trial and appeal, and across a wide range of
`
`technologies, including pharmaceutical-related technologies. Her pertinent
`
`biographical background appears in an addendum to her declaration. Id., ¶9 (citing
`
`EX1041 (Elham F. Steiner, Attorney Biography)).
`
`-3-
`
`
`
`Case No. IPR2018-01676
`Patent No. 8,603,044
`
`
`10. Ms. Steiner has reviewed in detail U.S. Patent No. 8,603,044 and the
`
`parties’ submissions in the present proceeding. EX1040, ¶10.
`
`III. REASONS FOR THE REQUESTED RELIEF
`Through Ms. Steiner’s representation in these and related matters, Mylan has
`
`
`
`developed a relationship with Ms. Steiner, which Mylan wants to continue for the
`
`purpose of these proceedings. Sanofi has asserted a large number of patents and
`
`claims against Mylan, making Ms. Steiner’s active involvement in all proceedings for
`
`purposes of coordination invaluable. Her educational background, general litigation
`
`experience, successful admission before other tribunals, and experience with this
`
`proceeding in particular make her well suited for pro hac vice admission in these
`
`proceedings.
`
`IV. DECLARATION OF MS. STEINER
`
`A declaration from Ms. Steiner (EX1040) accompanies this motion.
`
`V. CONCLUSION
`
`Good cause warrants the recognition of Ms. Steiner pro hac vice. Mylan
`
`respectfully requests that the Board grant this unopposed motion.
`
`
`
`
`Date: 28 February 2019
`
`
`
`
`Respectfully submitted,
`
`/ Wesley E. Derryberry /
`Wesley E. Derryberry, Back-up Counsel
`Reg. No. 71,594
`
`-4-
`
`
`
`Case No. IPR2018-01676
`Patent No. 8,603,044
`
`
`UPDATED EXHIBIT LIST
`
`
`Exhibit No.
`1001
`
`Description
`U.S. Patent 8,679,069, Pen-Type Injector (issued Mar. 25, 2014)
`
`1002
`
`1003
`
`1004
`
`1005
`
`1006
`
`1007
`
`1008
`
`1009
`
`1010
`
`1011
`
`1012
`
`1013
`
`1014
`
`1015
`
`U.S. Patent 8,603,044, Pen-Type Injector (issued Dec. 10, 2013)
`U.S. Patent 8,992,486, Pen-Type Injector (issued Mar. 31, 2015)
`
`U.S. Patent 9,526,844, Pen-Type Injector (issued Dec. 27, 2016)
`
`U.S. Patent 9,604,008, Drive Mechanisms Suitable for Use in Drug
`Delivery Devices (issued Mar. 28, 2017)
`File History for U.S. Patent 8,679,069
`
`File History for U.S. Patent 8,603,044
`
`File History for U.S. Patent 8,992,486
`
`File History for U.S. Patent 9,526,844
`
`File History for U.S. Patent. 9,604,008
`
`Expert Declaration of Karl Leinsing MSME, PE in Support of Petition
`for Inter Partes Review of U.S. Patent Nos. 8,679,069; 8,603,044;
`8,992,486; 9,526,844 and 9,604,008
`Curriculum Vitae of Karl Leinsing MSME,PE
`
`U.S. Patent 6,221,046 - A. Burroughs et al., “Recyclable Medication
`Dispensing Device” (issued Apr. 24, 2001)
`U.S. Patent 6,235,004 – S. Steenfeldt-Jensen & S. Hansen, “Injection
`Syringe” (issued May 22, 2001)
`U.S. Patent Application US 2002/0053578 A1 – C.S. Møller, “Injection
`Device” (pub’d May 2, 2002)
`
`-5-
`
`
`
`Case No. IPR2018-01676
`Patent No. 8,603,044
`
`Exhibit No.
`
`1016
`
`1017
`
`1018
`
`1019
`
`1020
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`Description
`U.S. Patent 6,932,794 B2 – L. Giambattista & A. Bendek, “Medication
`Delivery Pen” (issued Aug. 23, 2005)
`U.S. Patent 6,582,404 B1 – P.C. Klitgaard et al., “Dose Setting Limiter”
`(issued June 24, 2003)
`File History for U.S. Patent 6,582,404
`
`Plaintiffs’ Preliminary Claim Constructions and Preliminary
`Identification of Supporting Intrinsic and Extrinsic Evidence,
`Sanofi-Aventis U.S. LLC v. Mylan GmbH, No. 2:17-cv-09105
`(D.N.J.) (filed Sep. 5 2018)
`U.S. Patent 4,865,591 – B. Sams, “Measured Dose Dispensing Device”
`(issued Sep. 12, 1989)
`U.S. Patent 6,248,095 B1 – L. Giambattista et al., “Low-cost
`Medication Delivery Pen” (issued June 19, 2001)
`U.S. Patent 6,921,995 B1 – A.A. Bendek et al., “Medication Delivery
`Pen Having An Improved Clutch Assembly” (issued July 13, 1999)
`U.S. Patent 5,226,895 – D.C. Harris, “Multiple Dose Injection Pen”
`(issued July 13, 1993)
`U.S. Patent 5,851,079 – R.L. Horstman et al., “Simplified
`Unidirectional Twist-Up Dispensing Device With Incremental
`Dosing” (issued Dec. 22, 1998)
`Application as filed: U.S. Patent App. 14/946,203 – R.F. Veasey,
`“Relating to a Pen-Type Injector” (filed Nov. 19, 2015)
`GB 0304822.0 – “Improvements in and relating to a pen-type injector”
`(filed Mar. 3, 2003) (‘844 Priority Doc.)
`
`-6-
`
`
`
`Case No. IPR2018-01676
`Patent No. 8,603,044
`
`Exhibit No.
`
`1027
`
`1028
`
`1029
`
`1030
`
`1031
`
`1032
`
`1033
`
`1034
`
`1035
`
`Description
`WO 99/38554 – S.Steenfeldt-Jensen & S.Hansen, “An Injection
`Syringe” (pub’d Aug. 5, 1999) (Steenfeldt-Jensen PCT)
`Mylan GmbH and Biocon’s Preliminary Claim Constructions and
`Supporting Evidence Pursuant to L. Pat. R. 4.2, Sanofi-Aventis U.S.,
`LLC v. Mylan N.V., C.A. No. 17-cv-09105 (filed Sep. 5, 2018)
`Memorandum Opinion, Sanofi-Aventis U.S. LLC v. Merck Sharp &
`Dohme Corp., No. 16-cv-812 (filed Jan. 12, 2018)
`Memorandum Opinion, Sanofi -Aventis U.S. LLC v. Eli Lilly and Co.,
`No. 14-cv-113 (filed Jan. 20, 2015)
`N. Sclater & N.P. Chironis, Mechanisms & Mechanical Devices
`Sourcebook 191-95, “Twenty Screw Devices” (3d ed., July 2, 2001)
`EP 0 608 343 B1 – L. Petersen & N.-A. Hansen, “Large Dose Pen”
`(pub’d Oct. 18, 1991)
`A.G. Erdman &G.N. Sandor, “ Mechanical Advantage”, §3.7 in
`1 Mechanism Design: Analysis and Synthesis (1984)
`WO 01/83008 – S. Hansen & T.D. Miller., “An Injection Device, A
`Preassembled Dose Setting And Injection Mechanism For An
`Injection Device, And A Method Of Assembling An Injection Device”
`(pub’d Nov. 8, 2001)
`K.J. Lipska et al., Association of Initiation of Basal Insulin Analogs vs
`Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related
`Emergency Department Visits or Hospital Admissions and With
`Glycemic Control in Patients With Type 2 Diabetes, 320 J. Am.
`Med. Ass’n 53-62 (2018)
`
`-7-
`
`
`
`Case No. IPR2018-01676
`Patent No. 8,603,044
`
`Exhibit No.
`1036
`
`Description
`Transcript, Conference Call (January 15, 2019)
`
`1037
`
`1038
`
`1039
`
`1040
`
`1041
`
`
`
`
`
`Reserved
`
`Graph showing PTAB Days to Docketing for Review Proceedings filed
`between 2016-2018
`Reserved
`
`Declaration of Elham F. Steiner in Support of Petitioner’s Motion for
`Pro Hac Vice Admission
`Elham F. Steiner, Attorney Biography
`
`
`
`-8-
`
`
`
`Case No. IPR2018-01676
`Patent No. 8,603,044
`
`
`CERTIFICATE OF SERVICE
`
`I certify that on 28 February 2019 a true and correct copy of Unopposed
`
`Motion for Pro Hac Vice Recognition, EX1040, and EX1041 were served on the
`
`patent owner at the email correspondence addresses of the patent owner as follows:
`
`
`Elizabeth Stotland Weiswasser
`Anish R. Desai
`Kathryn M. Kantha
`William S. Ansley
`Matthew D. Sieger
`WEIL, GOTSHAL & MANGES LLP
`
`
`elizabeth.weiswasser@weil.com
`anish.desai@weil.com
`kathryn.kantha@weil.com
`sutton.ansley@weil.com
`matthew.sieger@weil.com
`Sanofi.IPR.Service@weil.com
`
`Respectfully submitted,
`
`
`
`
`Date: 28 February 2019
`
`
`
`
`/ Wesley E. Derryberry /
`Wesley E. Derryberry, Back-up Counsel
`Reg. No. 71,594
`
`
`
`-9-
`
`